Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Metrics to compare | OMER | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOMERPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −4.9x | −0.6x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | −1.8x | 1.3x | 2.6x | |
Price / LTM Sales | - | 7.3x | 3.1x | |
Upside (Analyst Target) | 229.9% | 122.1% | 55.8% | |
Fair Value Upside | Unlock | 13.6% | 7.3% | Unlock |